Evaluation of the BD OneFlow Acute Leukemia Panel (BD OneFlow ALOT, BCP-ALL T1, and AML T1-T4) on the BD FACSLyric Flow Cytometer Using Leftover, De-identified Specimens

Overview

This study is a multi-site, prospective performance study to determine equivalency between the investigational OneFlow Acute Leukemia Panel on the FACSLyric system versus the final clinical diagnosis.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Cross-Sectional
  • Study Primary Completion Date: July 25, 2022

Detailed Description

Hematology laboratories rely on flow cytometry technology (in addition to classic hematological methods) to aid in screening, diagnosing, and monitoring patients with hematological disorders. High speed and broad applicability of flow cytometry allows for the diagnosis. Currently, there are no consensus panels being used; consequently, the leukemia & lymphoma (L&L) testing remains a single-vial antibody being used, with various in-house laboratory developed tests (LDTs) being used to test patient specimens. Furthermore, the analysis of flow cytometer generated data is not standardized and requires a high level of expertise and training for interpretation of complex data. Therefore, optimized and standardized immunostaining protocols for the diagnosis, classification, and prognostic sub-classification of hematological malignancies are needed. Enrollment will occur at up to 8 investigational sites . Data will be acquired from Eligible remnant/leftover specimens on the BD FACSLyric flow cytometer and evaluated by site personnel and expert analysts . The final diagnosis and the affected cell population will be determined by site standard of care . Analysis of data will evaluate identification of 1) normal vs abnormal cell populations and 2) BCP-ALL, AML, and less certain diseases by the expert & site analysts as compared to the final diagnosis.

Interventions

  • Other: IUO Acute Leukemia Panel
    • This Investigational Panel , comprised of 6 reagents , is intended for in vitro diagnostic use for qualitative flow-cytometric immunophenotyping of immature hematopoietic cell populations. These reagents are used as an aid in the differential diagnosis of hematologically abnormal patients having, or suspected of having, B-cell acute lymphoblastic leukemia or acute myeloid leukemia.

Arms, Groups and Cohorts

  • Remnant/ Leftover specimens
    • Specimens that meet inclusion/exclusions criteria, are leftover from routine flow cytometry testing, and are from subjects having or suspected of having a hematological or non-hematological disorder.

Clinical Trial Outcome Measures

Primary Measures

  • Comparison between expert analysts’ determination of normal and abnormal specimen and final diagnosis (Sensitivity Analysis)
    • Time Frame: Within 24 Hours of specimen collection
    • Determine equivalence between the investigational OneFlow Acute Leukemia Panel on the BD FACSLyric system results analyzed by two independent experts versus the final clinical diagnosis for Normal (lymphoid and myeloid) or Abnormal (neoplastic lymphoid or myeloid) phenotypes. Sensitivity will be calculated
  • Comparison between expert analysts’ determination of normal and abnormal specimen and final diagnosis (Specificity Analysis)
    • Time Frame: Within 24 Hours of specimen collection
    • Determine equivalence between the investigational OneFlow Acute Leukemia Panel on the BD FACSLyric system results analyzed by two independent experts versus the final clinical diagnosis for Normal (lymphoid and myeloid) or Abnormal (neoplastic lymphoid or myeloid) phenotypes. Specificity will be calculated

Participating in This Clinical Trial

Inclusion Criteria

1. Specimen collected/handled prior to enrollment in accordance with site policies and procedures. 2. Specimen with adequate volume (1 mL) to complete protocol tests. 3. Specimen is leftover PB and BM from routine flow cytometry laboratory testing for having or suspected of having acute leukemia disorders (i.e. AML, BCP-ALL, ALAL, etc.), myelodysplastic syndrome (MDS), other hematological, or non-hematological disorders. 4. Specimen from newly diagnosed or relapsed subject. 5. Only one specimen type (PB or BM) shall be enrolled per given subject. 6. Specimen is stored at room temperature, upon receipt by the site. 7. Specimens are collected in EDTA (K2 or K3) or heparin (sodium or lithium). 8. Age of specimen (BCP ALL T1: time of collection to start of first pre-wash; ALOT, AML T1-T4: time of collection to start of staining): ≤ 24 hours. 9. Specimens are from subjects irrespective of race, gender, and ethnicity Exclusion Criteria:

1. Specimen is from healthy subject. 2. Specimen from subject <3 years of age. 3. Specimen is from subject undergoing any treatment for any form of leukemia. 4. Specimen is from subject with minimal residual disease (MRD) as determined by the site. 5. Specimen is from subject suspected of plasma cell disorders. 6. Visibly clotted specimen. 7. Visibly hemolyzed specimen. 8. Frozen specimen. 9. Refrigerated specimen. 10. Fixed specimen.

Gender Eligibility: All

Minimum Age: 3 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Becton, Dickinson and Company
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Imelda Omana-Zapata, MD, PHD, Study Director, Becton, Dickinson and Company
  • Overall Contact(s)
    • Kimberly Dean, 669-254-0972, kimberly_dean@bd.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.